MARKET

QTTB

QTTB

Q32 BIO INC
NASDAQ
2.000
+0.160
+8.70%
After Hours: 2.000 0 0.00% 16:05 03/14 EDT
OPEN
1.850
PREV CLOSE
1.840
HIGH
2.010
LOW
1.850
VOLUME
121.08K
TURNOVER
--
52 WEEK HIGH
53.79
52 WEEK LOW
1.800
MARKET CAP
24.36M
P/E (TTM)
-0.3905
1D
5D
1M
3M
1Y
5Y
1D
Q32 Bio Price Target Cut to $15.00/Share From $16.00 by Wells Fargo
Dow Jones · 3d ago
Q32 Bio Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 3d ago
Wells Fargo Maintains Equal-Weight on Q32 Bio, Lowers Price Target to $15
Benzinga · 3d ago
Q32 BIO INC <QTTB.O>: WELLS FARGO CUTS TARGET PRICE TO $15 FROM $16
Reuters · 3d ago
U.S. RESEARCH ROUNDUP-AbbVie, Dick's Sporting, Oracle
Reuters · 4d ago
Q32 Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 4d ago
Q32 Bio GAAP EPS of -$1.16 beats by $0.37
Seeking Alpha · 4d ago
Q32 Bio Q4 2024 GAAP EPS $(1.16) Beats $(1.51) Estimate, Cash And Cash Equivalents Of $78M As Of December 31, 2024 Expected To Provide Financial Runway Into 2H 2026
Benzinga · 4d ago
More
About QTTB
Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.

Webull offers Q32 Bio Inc stock information, including NASDAQ: QTTB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QTTB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QTTB stock methods without spending real money on the virtual paper trading platform.